Ann: Appendix 4C - quarterly-AHZ.AX, page-79

Yeah this sounds really great. Unfortunately I'm going to be stuck on a plane at that time. if anyone is able to record and post the webinar, id be eternally grateful.

If anyone is asking questions here are some of mine (im surely many here are already going to ask similar ones anyway).

1 Take-up: What are the key barriers to take-up growth?
a) Do these include existing contacts between hospitals and ahz competitors?
b) Do hospitals carry a large inventory of patches that they have to work through before they reorder? I.e. do we have to wait till many hospitals finish their supplies of competitor patches?

2) Why has Chinese market approval not been sought to date?

3) How does the company propose to avoid a cap raise next quarter, is it realistic to expect cash burn to be reduced?
a) can they provide guidence on expected cost reductions (in aggregate or by type (e.g working capital, staff costs etc))
b) can investment in the pipeline be pushed back a quarter or 2 to avoid a CR to after better cc sales and vax